Clinical trials treating relapsed and refractory B-ALL patients with anti-CD19 CAR-Ts (CAR19-Ts) reported remarkable results with remission rates between 68–93% [10,11]. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.